These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 22708837)
1. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837 [TBL] [Abstract][Full Text] [Related]
2. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326 [TBL] [Abstract][Full Text] [Related]
3. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886 [TBL] [Abstract][Full Text] [Related]
4. Ad5 Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908 [No Abstract] [Full Text] [Related]
5. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Toivonen R; Suominen E; Grenman R; Savontaus M Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458 [TBL] [Abstract][Full Text] [Related]
6. A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects. Mei S; Peng S; Vong EG; Zhan J Int Immunopharmacol; 2024 Aug; 137():112393. PubMed ID: 38852522 [TBL] [Abstract][Full Text] [Related]
7. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007 [TBL] [Abstract][Full Text] [Related]
9. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Wohlfahrt ME; Beard BC; Lieber A; Kiem HP Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719 [TBL] [Abstract][Full Text] [Related]
10. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824 [TBL] [Abstract][Full Text] [Related]
11. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567 [TBL] [Abstract][Full Text] [Related]
12. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292 [TBL] [Abstract][Full Text] [Related]
14. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Nakamura T; Sato K; Hamada H Hum Gene Ther; 2002 Mar; 13(5):613-26. PubMed ID: 11916485 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice. Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803 [TBL] [Abstract][Full Text] [Related]
16. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Smith TA; Idamakanti N; Rollence ML; Marshall-Neff J; Kim J; Mulgrew K; Nemerow GR; Kaleko M; Stevenson SC Hum Gene Ther; 2003 May; 14(8):777-87. PubMed ID: 12804140 [TBL] [Abstract][Full Text] [Related]
18. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer. Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292 [TBL] [Abstract][Full Text] [Related]
19. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]